SCHEMBL1662090

SCHEMBL1662090

CC(C)(C)OC(=O)[C@H](CC(=O)O)C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
GAA P10253 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
PGD P52209 1/20 0.35
SLC22A6 Q4U2R8 1/20 0.33
AAK1 Q2M2I8 1/20 0.33
LMNA P02545 1/20 0.32
CYP2D6 P10635 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA7 P43166 1/20 0.32
DGAT1 O75907 1/20 0.31
FOLH1 Q04609 1/20 0.31
NOS1 P29475 2/20 0.31
NOS3 P29474 1/20 0.31
NOS2 P35228 1/20 0.31
HMGCR P04035 1/20 0.31
CHRM1 P11229 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1662092 1.00 KMT2A (0.38) KMT2AMEN1GAATDP1SMN1; SMN2
SCHEMBL344597 0.85 HDAC3 (0.44) KMT2AMEN1GAAAAK1LMNA
SCHEMBL344596 0.85 HDAC3 (0.44) KMT2AMEN1GAAAAK1LMNA
SCHEMBL28086823 0.84 KMT2A (0.39) KMT2AMEN1GAATDP1SMN1; SMN2
SCHEMBL28250949 0.82 MEN1 (0.35) KMT2AMEN1GAAAAK1
SCHEMBL3325728 0.82 KMT2A (0.39) KMT2AMEN1GAACYP2D6CA1
SCHEMBL11048601 0.82 TDP1 (0.33) TDP1SMN1; SMN2PGDSLC22A6CYP2D6
SCHEMBL3325735 0.82 KMT2A (0.39) KMT2AMEN1GAACYP2D6CA1
SCHEMBL4897617 0.81 KMT2A (0.33) KMT2AMEN1GAAPGDCYP2D6
SCHEMBL28184673 0.80 MEN1 (0.34) KMT2AMEN1GAAAAK1NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2306994-B1 S1P1 RECEPTOR AGONISTS AND USE THEREOF AMGEN INC (US) 2013-08-14 EP disclosed
EP-2306994-A1 S1P1 RECEPTOR AGONISTS AND USE THEREOF Amgen, Inc (US) 2011-04-13 EP disclosed
US-7842685-B2 S1P1 receptor agonists and use thereof AMGEN INC. (US) 2010-11-30 US disclosed
US-20100029611-A1 S1P1 receptor agonists and use thereof AMGEN INC. (US) 2010-02-04 US disclosed
WO-2009154775-A1 S1P1 RECEPTOR AGONISTS AND USE THEREOF AMGEN INC. (US) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029611-A1 S1P1 receptor agonists and use thereof S1PR1, S1PR5, S1PR2 KMT2A 3037/4885MEN1 684/4885GAA 4071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.